Page last updated: 2024-12-07

sk&f 105685

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F 105685: an azaspirane; structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121957
CHEMBL ID101018
SCHEMBL ID7920522
MeSH IDM0172158

Synonyms (18)

Synonym
skf-105685
sk&f-105685
skf 105685
n,n-dimethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine
2-azaspiro(4.5)decane-2-propanamine, n,n-dimethyl-8,8-dipropyl-
n,n-dimethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamide
sk&f 105685
CHEMBL101018
93772t99mp ,
123018-34-8
unii-93772t99mp
n,n-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine
AQQJKZQCFJQLOU-UHFFFAOYSA-N
n,n-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine
SCHEMBL7920522
3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine
DTXSID50924348
Q27271570

Research Excerpts

Dosage Studied

SK&F 105685 (20 mg/kg/day) effectively halted disease progression, and the inflammatory lesion was suppressed by 70% following treatment for 20 days.

ExcerptRelevanceReference
" To evaluate the immunotoxicologic potential of SK&F 105685, the effect on immune function of one month of dosing with 1 mg/kg/day of SK&F 105685 was examined in the dog."( Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog.
Badger, AM; Bugelski, PJ; Kaplan, JM; Ruggieri, EV; Swift, BA, 1993
)
0.93
" In a therapeutic protocol, where dosing was initiated on day 10 after disease induction, SK&F 105685 (20 mg/kg/day) effectively halted disease progression, and the inflammatory lesion was suppressed by 70% following treatment for 20 days."( Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression.
Badger, AM; Bugelski, PJ; Clark, RK; Griswold, DE; Swift, BA; Webb, EF, 1993
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID196505Total starting number of animals upon administration at a dose of 30 mg/kg; 8/81990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
AID196495Total starting number of animals upon administration at a dose of 15 mg/kg; 8/81990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
AID14903Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
AID168228Adjuvant arthritic rat activity with respect to spirogermanium at a dose of 15 mg/kg1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
AID196506Total starting number of animals upon administration at a dose of 60 mg/kg; 0/61990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
AID168231Adjuvant arthritic rat activity determined with respect to spirogermanium at a dose of 30 mg/kg1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.00)18.7374
1990's19 (95.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.76 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]